Back to top
more

Moderna (MRNA)

(Delayed Data from NSDQ)

$68.28 USD

68.28
11,965,096

-1.40 (-2.01%)

Updated Sep 13, 2024 04:00 PM ET

After-Market: $67.82 -0.46 (-0.67%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Kinjel Shah headshot

Pfizer COVID-19 Vaccine Data Raises Hopes for Industry, Economy

Pfizer (PFE)/BioNTech's (BNTX) COVID-19 vaccine candidate proves to be 90% effective in phase III.

Tirthankar Chakraborty headshot

2 Stocks to Watch on Pfizer's 90% Effective COVID-19 Vaccine

Pfizer's (PFE) shares hit an all-time high during yesterday's trading session on its milestone COVID-19 vaccine news, while Moderna's (MRNA) soared on optimism as it applies a similar technology.

Positive News on COVID-19 Vaccine

Positive News on COVID-19 Vaccine

Mark Vickery headshot

Pfizer's Covid Drug Proves 90%+ Effective; PFE, BNTX

A Covid vaccine takes the lid off most everything market-related. That said, we're still looking at a period of months before it would be widely available.

Moderna (MRNA) Q3 Earnings Lag Estimates, Pipeline Advances

Moderna (MRNA) reports wider-than-expected third-quarter loss. However, revenues beat estimates significantly. Shares up presumably on encouraging pipeline progress and rising cash resources.

Vertex (VRTX) Beats on Q3 Earnings & Sales, Ups Sales View

Vertex (VRTX) beats estimates for both earnings and sales and raises revenue guidance for 2020.

Company News for Oct 30, 2020

Companies in The News Are: NFLX, MRNA, IPHI, MRVL, RL.

Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates

Moderna (MRNA) delivered earnings and revenue surprises of -37.21% and 103.70%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

John Blank headshot

Update on the COVID Vaccine Race

A 2021 Macro Recovery is About This, Alone.

Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?

Investors' focus is likely to be on any update on the timeline for filing for emergency use authorization of Modena's (MRNA) coronavirus vaccine candidate on the third-quarter earrings call.

The Zacks Analyst Blog Highlights: Netflix, Lockheed, Zoetis, ITUB and Moderna

The Zacks Analyst Blog Highlights: Netflix, Lockheed, Zoetis, ITUB and Moderna

Moderna (MRNA) Stock Sinks As Market Gains: What You Should Know

Moderna (MRNA) closed at $70.53 in the latest trading session, marking a -0.44% move from the prior day.

Mark Vickery headshot

Top Analyst Reports for Netflix, Lockheed Martin & Zoetis

Today's Research Daily features new research reports on 12 major stocks, including Netflix (NFLX), Lockheed Martin (LMT) and Zoetis (ZTS).

Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline

Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AstraZeneca (AZN), J&J (JNJ) Coronavirus Trials May Resume Soon

Clinical studies on coronavirus vaccine candidates of AstraZeneca (AZN) and J&J (JNJ) which were paused for reviewing adverse events are anticipated to resume as early as this week.

Merck (MRK) Pneumococcal Vaccine Meets Late-Stage Study Goals

Merck's (MRK) investigational 15-valent pneumococcal conjugate vaccine meets primary immunogenicity objectives in two late-stage studies in adults.

Sanofi's mRNA Vaccine for Coronavirus to Enter Clinical Stage

Sanofi (SNY) and Translate Bio select coronavirus vaccine candidate MRT5500 for clinical development, based on its promising pre-clinical data. A clinical study is anticipated by this year-end.

Moderna (MRNA) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Moderna (MRNA) closed at $75.58, marking a -1.28% move from the previous day.

Moderna Gets Consent to File MAA for Coronavirus Vaccine in EU

Moderna (MRNA) gets permission from the European Medicines Agency to submit a marketing authorization application for mRNA-1273, its vaccine candidate against COVID-19.

Vaxart (VXRT) Begins Dosing in Oral Coronavirus Vaccine Study

Vaxart (VXRT) doses the first subject in an early-stage study of its oral coronavirus vaccine candidate VXA-CoV2-1. Stock rises.

J&J's Coronavirus Vaccine Studies Paused Post Adverse Event

J&J's (JNJ) large phase III ENSEMBLE study on its coronavirus vaccine candidate, JNJ-78436735, is expected to enroll 60,000 adult participants and compares a single dose of the vaccine to placebo.

Zacks.com featured highlights include: NetEase, USA Truck, AXT and Moderna

Zacks.com featured highlights include: NetEase, USA Truck, AXT and Moderna

Sweta Killa headshot

Here's Why Small-Cap ETFs Are Hitting New Highs

Small-Cap ETFs hit new highs in the recent trading session. We have highlighted some solid reasons for their strong performance.

Tirthankar Chakraborty headshot

4 Stocks With Solid Earnings Acceleration to Watch

If the rate of a company's quarter-over-quarter earnings growth increases within a stipulated frame of time, it can be called earnings acceleration.

Moderna (MRNA) Stock Moves -1.26%: What You Should Know

In the latest trading session, Moderna (MRNA) closed at $71.04, marking a -1.26% move from the previous day.